|
Midazolam Clinical Trials
15 actively recruiting trials across 7 locations
▲ +5 trials since June 2026
Also known as: Dormicum, Hypnovel, Randomized Controlled Phase Intervention 2, Seizalam
Pipeline
Phase 1: 6Phase 3: 3Phase 4: 1Phase 1/2: 1
Top Sponsors
- Pfizer3
- Yangzhou University1
- University Hospital, Montpellier1
- Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital1
- Nuvalent Inc.1
Indications
- Cancer7
- Anxiety4
- Heart Disease2
- Advanced Malignancies2
- Lung Cancer2
Other7 trials
Phase 3
Birmingham, Alabama2 trials
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
University of Alabama at Birmingham
Phase 3
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
University of Alabama at Birmingham
Phase 3
Fayetteville, Arkansas1 trial
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Highlands Oncology Group
Phase 1
Orange, California1 trial
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
University of California Irvine Medical Center
Phase 1/2
New Haven, Connecticut1 trial
A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma
Pfizer Clinical Research Unit - New Haven
Phase 1
Orlando, Florida1 trial
Glenview, Illinois1 trial
Phase 4
Nashville, Tennessee1 trial
An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers
Sarah Cannon Research Institute - Pharmacy
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.